Annual report


The guidelines group last met on 8th November 2016 at the headquarters of the British Society for Haematology (BSH).

The guidelines group continues to work very closely with Myeloma UK in the development of guidelines and position statements.

The NICE myeloma guideline was published in February 2016 (It does not address any area covered by existing NICE technology appraisals which covers most treatments at induction and relapse). The aim has been to promote the NICE guideline more widely, and to that end we produced an editorial that was published in the International Journal of Laboratory Haematology in 2016.

The British Society for Haematology approach to guidelines is changing with a focus on publishing a smaller number of guidelines each year that are NICE accredited. It is inevitable that some future myeloma guidelines and related plasma cell disorder guidelines will be outside this process, and most likely published as expert opinion papers rather than guidelines.

The UKMF Guidelines Group guidelines on The Diagnosis and Management of Multiple Myeloma 2011 have now been archived on the BSH web site. The Supportive Care in Multiple Myeloma 2011 guidelines are still available, but they have been superceded to some extent by the recent Screening and Management of Late and Long Term Consequences of Myeloma and its Treatment 2017 guidelines, which are on the BSH web site and were published in the British Journal of Haematology.

We expect that guidelines on Imaging in Multiple Myeloma will be also be published in 2017, both on-line and in the British Journal of Haematology.

Recent publications

  •  Optimising the management of patients with spinal myeloma disease (British Journal of Haematology 2015).
  • Time to redefine myeloma (new IMWG definition of myeloma) (British Journal of Haematology 2015).
  • Two guidelines on AL amyloidosis, one guideline on the diagnosis and investigation and a second guideline on management, were published in the British Journal of Haematology in 2015.

 

Future work plans

The UKMF Guidelines Group will need to consider how it needs to modify its approach to the production of its guidelines in the light of the imminent changes to BSH guidelines as a whole. It is likely that the Group will produce some Good Practice Papers, covering discrete areas of myeloma practice, in order to maintain its output. Possible topics already suggested for such papers include:

Non-imaging diagnostics

The mangment of renal disease in myeloma

First line treatments in transplant-eligible and non-eligible patients.